Cancer genomics has revolutionized personalized medicine in oncology. By understanding the specific genetic alterations in a patient's tumor, clinicians can select targeted therapies that are more effective. For instance, mutations in the EGFR gene can be targeted by EGFR inhibitors in lung cancer patients. Similarly, PARP inhibitors are effective in treating cancers with BRCA1 or BRCA2 mutations.
